1 |
Altman, D. G. (1980). Statistics and ethics in medical research, III: How large a sample? The British Medical Journal, 281, 1336-1338.
DOI
|
2 |
Chow, S. C. (2014). Biosimilars: Design and Analysis of Follow-on Biologics, CRC Press, Boca Raton, Florida.
|
3 |
Chow, S. C., Hsieh, T. C., Chi, E. and Yang J. (2009). A comparison of moment-based and probabilitybased criteria for assessment of follow-on biologics, Journal of Biopharmaceutical Statistics, 20, 31-45.
DOI
ScienceOn
|
4 |
Chow, S. C. and Liu, J. P. (2010). Statistical assessment of biosimilar products, Journal of Biopharmaceutical Statistics, 20, 10-30.
|
5 |
Chow, S. C., Shao, J. and Wang, H. (2003). Sample Size Calculations in Clinical Research, Marcel Dekker, New York.
|
6 |
Chow, S. C., Wang, J., Endrenyi, L. and Lachenbruch, P. A. (2013). Scientific considerations for assessing biosimilar products, Statistics in Medicine, 32, 370-381.
DOI
ScienceOn
|
7 |
Hsieh, T. C., Chow, S. C., Yang, L. Y. and Chi, E. (2013). The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics, Statistics in Medicine, 32, 406-414.
DOI
ScienceOn
|
8 |
Kang, S. H. and Chow, S. C. (2013). Statistical assessment of biosimilarity based on relative distance between follow-on biologics, Statistics in Medicine, 32, 382-392.
DOI
ScienceOn
|
9 |
Kang, S. H. and Kim, Y. (2014). Sample size calculations for the development of biosimilar products. Journal of Biopharmaceutical Statistics, 24, 1215-1224.
DOI
ScienceOn
|
10 |
Li, Y., Liu, Q., Wood, P. and Johri, A. (2013). Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins, Statistics in Medicine, 32, 393-405.
DOI
ScienceOn
|
11 |
Moher, D., Dulberg, C. S. and Wells, G. A. (1994). Statistical power, sample size, and their reporting in randomized controlled trials, Journal of the American Medical Association, 272, 122-124.
DOI
ScienceOn
|
12 |
Sinclair, J. C. and Bracken, M. B. (1994). Clinically useful measures of effect in binary analyses of randomized trials, Journal of Clinical Epidemiology, 47, 881-889.
DOI
ScienceOn
|
13 |
US Food and Drug Administration (2012). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, US Food and Drug Administration, Rockville, MD.
|
14 |
Walter, S. D. (2000). Choice of effect measure for epidemiological data, Journal of Clinical Epidemiology, 53, 931-939.
DOI
ScienceOn
|
15 |
Wang, H., Chow, S. C. and Li, G. (2002). On sample size calculation based on odds ratio in clinical trials, Journal of Biopharmaceutical Statistics, 12, 471-483.
DOI
ScienceOn
|
16 |
World Health Organization (2009). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), World Health Organization, Geneva.
|